(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement applauding the Maryland legislature and Governor Larry Hogan for enacting first-of-its-kind legislation, HB 978/SB 915, to increase transparency in the prescription drug supply chain. The legislation,
Today’s announcement by the Administration to include greater use of PBM tools in Medicare Part B through Medicare Advantage Prescription Drug Plans is an important step toward reducing costs for the program and beneficiaries,” PCMA said in a statement.
The increases were effective as of July 1 and in most cases were just over 9 per cent — well above the rate of inflation in the US, which is running at about 2 per cent.
America’s Pharmacy Benefit Managers (PBMs) agree with the Administration and Patients. The most direct way to reduce costs and improve access to prescription drugs is for drugmakers to cut their prices. See the new PCMA Ad
the drug company Bayer hiked the list prices of two cancer drugs by more than $1,000 per month.
“I think what happened is they looked at this policy very, very closely and found out it was a loser,” PCMA President Mark Merritt said.
Greater competition is the answer, Mr. Merritt said, and he praised recent efforts by the Food and Drug Administration
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director and chief economist for the U.S. House Committee on Ways and Means, “Rebates and Drug
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
©2024 PCMA. All Rights Reserved.
